rte: Sep. 12 <sup>th</sup> , 2023
ur Name: Luchun Li Luchun Li
anuscript Title: Fruquintinib in Combination with Sintilimab or TAS-102 as Third-Line or above
eatment in Patients with Metastatic Colorectal Cancer: A Real-World Study
anuscript number (if known): TCR-23-867-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

196		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
3615	20.16.2 年 20.7 年 20.00 日 月 1月 1月 1日	Time trame. Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
		Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission: Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
¥.	3/2/14/16/4/16	Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in	XNone	

	in item #1 above).					
3		V News				
3	Royalties or licenses	X_None				
4	Consulting fees	XNone				
				*		
5	Payment or honoraria for	X None			<u> </u>	
	lectures, presentations,					
	speakers bureaus,			***		
	manuscript writing or		1			
	educational events					
6	Payment for expert	X None				
	testimony					
7	Support for attending	XNone				
	meetings and/or travel					
8	Patents planned, issued or	XNone				
	pending					
	1					
9	Participation on a Data	X None	8		·	
	Safety Monitoring Board or			***************************************		
	Advisory Board					
10	Leadership or fiduciary role	X None				
	in other board, society,				**************************************	
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	V None				
11	Stock of Stock options	X_None				
				· · · · · · · · · · · · · · · · · · ·		
	***************************************					
12	Receipt of equipment,	X_None				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	X None			· ·	
13	financial interests					
	,anciar interests					

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 1	2 <sup>th</sup> , 2023			
Your Name:	Ting Wang	Ting	Wong.	
Manuscript Title	e: Fruqui	intinib in C	ombinatio	n with Sintilimab or TAS-102 as Third-Line or above
				cer: A Real-World Study
Manuscript nun	nber (if known):	TCR-23-8	67-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
	medical writing, article processing charges, etc.)  No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission; Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
2	Grants or contracts from	Time frame: pastXNone	36 months
	any entity(if not indicated in		

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. :	12 <sup>th</sup> , 2023	
Your Name:	Zhijuan Wu	Zhiiuan Wu
Manuscript Titl	e: Fruqui	ntinib in Combination with Sintilimab or TAS-102 as Third-Line or above
Treatment in P		static Colorectal Cancer: A Real-World Study
Manuscript nui	mber (if known): _	TCR-23-867-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
900	音樂。在多數學是對稱其中學的問題的	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
	medical writing, article processing charges, etc.) No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission: Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
10/5		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 12th, 2023	
Your Name: Yan Li	
Manuscript Title:	Fruquintinib in Combination with Sintilimab or TAS-102 as Third-Line or above
Treatment in Patients v	vith Metastatic Colorectal Cancer: A Real-World Study
	nown):TCR-23-867-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame. Since the lintal	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
		Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission; Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
		,	
A Land	图图:2011年1月1日 1月1日 1月1日 1月1日	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 12	<sup>th</sup> , 2023		
Your Name:	Huiwen Ma	Huiwer Ma	
Manuscript Title:	Fruqui	ntinib in Combination	with Sintilimab or TAS-102 as Third-Line or above
Treatment in Pati	ients with Meta	static Colorectal Cance	er: A Real-World Study
Manuscript numb	er (if known):	TCR-23-867-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	表示 医多种 的复数形式 医脓性	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
	medical writing, article processing charges, etc.) No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission; Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 12	<sup>th</sup> , 2023			
Your Name:	Lulu Wang	Lula	Wang	
Manuscript Title:	Fruguinti	nib in Combin	nation w	ith Sintilimab or TAS-102 as Third-Line or above
Treatment in Pat	ients with Metasta	tic Colorecta	I Cancer:	A Real-World Study
Manuscript num	ber (if known): _T(	CR-23-867-CL		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Chongqing Natural Science	Chongqing Municipal Commission of science and
1	manuscript (e.g., funding, provision of study materials,	Foundation (grant nos. cstc2018jcyjAX0814)	technology
	medical writing, article processing charges, etc.) No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission; Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 12th	, 2023
Your Name:	Shuangyi Lei Shuangyi Lei
Manuscript Title:	
Treatment in Patie	ents with Metastatic Colorectal Cancer: A Real-World Study
Manuscript number	er (if known): TCR-23-867-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
No.		Time trame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
	medical writing, article processing charges, etc.) No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission: Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
		,	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement:

Date: Sep. 12	th, 2023		
Your Name:	Wen Chen	Wen Chen.	
Manuscript Title:	Fruquir	ntinib in Combinati	on with Sintilimab or TAS-102 as Third-Line or above
Treatment in Pati			ncer: A Real-World Study
Manuscript numb	er (if known): _	TCR-23-867-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	<b>企业的证据。但该企图,并是</b>	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Chongqing Natural Science Foundation (grant nos. cstc2018jcyjAX0814)	Chongqing Municipal Commission of science and technology
	medical writing, article processing charges, etc.) No time limit for this item.	Chongqing Science and Health Joint Project (grant no. 2022MSXM131)	Chongqing Municipal Health Commission: Chongqing Municipal Bureau of science and technology
		2021 Chongqing Young and Middle-aged Medical High-end Talent Project	Chongqing Municipal Health Commission
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in	XNone	

	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	*	 4	
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	999		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			

The author reports receiving funding from the Chongqing Natural Science Foundation (No. cstc2018jcyjAX0814), Chongqing Science and Health Joint Project (No. 2022MSXM131) and 2021 Chongqing Young and Middle-aged Medical High-end Talent Project.

Please place an "X" next to the following statement to indicate your agreement: